# 智谱清言 GLM 5.2 网页版 · 三段完整回答（外部附录）

> 本文件为「框架 v1.0」实测中 **智谱清言 ChatGLM 5.2 网页版** 三次运行的**完整原文**，
> 供逐条核对评分使用。正文分析报告见 `chatglm_report.html`，此处不重复分析。
>
> ⚠️ **重要观察：三段回答均为英文，而输入 Prompt 与病历均为中文。**
> 这意味着 GLM 5.2 在该任务上默认/强制使用英文输出，对中文临床用户构成独立的可用性硬伤。

---

## 测试 1（Run 1）

Based on the medical record provided, I can see this is a 60-year-old female patient with right breast cancer who has undergone surgery. The tumor shows:
- ER positive (3+, 90%)
- PR positive (3+, 90%)
- Her-2 negative
- Low Ki-67 (5%)
- Stage 0 (TisN0M0)

Typical next therapy for this type of breast cancer would be:
- **Endocrine therapy (hormonal therapy)** - This is already mentioned as "术后予内分泌治疗" in the record. Given the strong hormone receptor positivity (both ER and PR are 90% positive), endocrine therapy would be the standard recommendation.
- **Follow-up monitoring** - Regular check-ups and imaging as determined by the oncologist.

Important considerations:
- The specific endocrine therapy regimen (tamoxifen or aromatase inhibitor) would depend on menopausal status and other factors
- Duration of therapy would typically be 5-10 years for hormone receptor positive early-stage breast cancer
- Regular monitoring for recurrence and potential side effects

Please note: This is general information based on the medical record. The actual treatment plan should be determined by the patient's oncologist, who can provide personalized recommendations based on the complete clinical picture and latest treatment guidelines.

Would you like me to explain any specific aspect of breast cancer treatment in more detail?

---

## 测试 2（Run 2）

Based on the medical record provided, here's what I can see regarding the patient's condition and next therapy considerations:

**Patient Information:**
- 60-year-old female with right breast cancer
- Underwent surgery on 2026-04 (right breast simple mastectomy + sentinel lymph node biopsy)
- Pathology: Invasive ductal carcinoma, stage TisN0M0 (0 stage)
- Favorable hormone receptor status: ER (3+, 90%), PR (3+, 90%), Her-2 negative

**Current Status:**
- Already on postoperative endocrine therapy
- No symptoms (no cough, no sputum, no dizziness/headache)
- Requires follow-up

**Next Therapy Considerations:**
For this early-stage hormone receptor positive breast cancer (stage 0), the typical next steps would likely include:
- **Continuation of adjuvant endocrine therapy** - This appears to already be in progress
- **Regular follow-up monitoring** - As indicated in the record
- **Possible radiation therapy** - Depending on surgical margins and other factors (not explicitly mentioned in this record)

The specific next therapy would be determined by the oncologist based on standard treatment guidelines for early-stage hormone receptor positive breast cancer, considering the patient's complete pathology report and individual risk factors.

Important Note: This is medical information interpretation only. The actual treatment plan should be determined by the patient's oncologist based on comprehensive evaluation and current clinical guidelines.

---

## 测试 3（Run 3）

Based on the medical record provided, I can see this is a 60-year-old female patient with right breast cancer who underwent surgery in April 2026. The pathology shows:
- Invasive ductal carcinoma with ductal carcinoma in situ
- Tumor size 0.6cm
- ER positive (3+, 90%) and PR positive (3+, 90%)
- Her-2 negative
- Ki-67 5% (low proliferation rate)
- Stage TisN0M0 (Stage 0)

Given these findings, the typical next therapy would be:
- **Adjuvant Endocrine Therapy** - Since the tumor is ER/PR positive (hormone receptor positive), endocrine therapy (such as aromatase inhibitors or tamoxifen) would be the standard treatment to prevent recurrence. The patient appears to already be on endocrine therapy according to the record.
- **Follow-up Monitoring** - Regular follow-up appointments and imaging as recommended by the oncologist.

However, I must emphasize that I am not a medical professional and cannot provide specific medical advice. The patient should:
- Consult with their oncologist for personalized treatment recommendations
- Discuss the specific type and duration of endocrine therapy
- Follow the recommended surveillance schedule

The treatment plan should be individualized based on the complete medical evaluation and discussion with the healthcare team.